Literature DB >> 22583337

No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours.

Carla Pelusi1, Giulia Forlani, Laura Zanotti, Alessandra Gambineri, Renato Pasquali.   

Abstract

AIM: To examine the impact of surgical normalization of testosterone on body weight and on glucose and lipid metabolism and insulin sensitivity in a group of hyperandrogenic women with ovarian androgen-secreting tumours (OAST).
METHODS: Five consecutive postmenopausal hyperandrogenic patients (aged 63 ± 5 years) with a diagnosis of OAST were prospectively evaluated. Clinical signs, symptoms and metabolic and hormonal parameters were collected at the time of the diagnosis and at follow-up, 12 months after surgical oophorectomy. A group of 15 age-matched and body mass index-matched postmenopausal control women served as a reference group.
RESULTS: At baseline, patients with OAST had very high testosterone levels and inappropriately low gonadotrophin levels for their menopausal status. All the women were overweight or obese, and one had a history of polycystic ovary syndrome and Type 2 diabetes. Twelve months after surgical oophorectomy, testosterone and gonadotrophin levels returned to appropriate values for menopausal status in all patients; however, no change in body weight was found. Fasting glucose levels slightly increased (P < 0·05) without any significant change in other metabolic parameters. In the woman with diabetes, a moderate decrease in haemoglobin A1c occurred. Red blood cell count and haematocrit values were normalized (P < 0·05, respectively).
CONCLUSION: Normalization of androgen levels achieved after surgical oophorectomy did not cause any significant change in body weight and insulin sensitivity. These findings may offer a different perspective on the impact of hyperandrogenaemia on metabolism.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22583337     DOI: 10.1111/j.1365-2265.2012.04438.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

Review 1.  Cardiovascular risk factors and events in women with androgen excess.

Authors:  D Macut; I B Antić; J Bjekić-Macut
Journal:  J Endocrinol Invest       Date:  2014-11-29       Impact factor: 4.256

2.  MENOPAUSAL ANDROGEN EXCESS - ASSOCIATED CARDIO-METABOLIC RISK: CLUES FOR OVARIAN LEYDIG CELL TUMOUR (CASE REPORT AND MINI-REVIEW OF LITERATURE).

Authors:  A A Gheorghisan-Galateanu; D Terzea; A Valea; M Carsote
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Jul-Sep       Impact factor: 0.877

3.  Persistent Poor Metabolic Profile in Postmenopausal Women With Ovarian Hyperandrogenism After Testosterone Level Normalization.

Authors:  Thaís Rocha; Raiane P Crespo; Viviane V R Yance; Sylvia A Hayashida; Edmund C Baracat; Filomena Carvalho; Sorahia Domenice; Berenice B Mendonca; Larissa G Gomes
Journal:  J Endocr Soc       Date:  2019-04-04

Review 4.  The Masquerading, Masculinizing Tumor: A Case Report and Review of the Literature.

Authors:  Alexis LeVee; Nissi Suppogu; Christine Walsh; Wendy Sacks; James Simon; Chrisandra Shufelt
Journal:  J Womens Health (Larchmt)       Date:  2020-09-29       Impact factor: 3.017

5.  Occult leydig cell tumour and androgen-receptor positive breast cancer in a woman with severe hyperandrogenism.

Authors:  Giovanna Saraceno; Valeria Barresi; Francesco Trimarchi; Salvatore Cannavo
Journal:  J Ovarian Res       Date:  2013-07-01       Impact factor: 4.234

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.